Marinus van Oers

745 total citations
17 papers, 325 citations indexed

About

Marinus van Oers is a scholar working on Genetics, Hematology and Molecular Biology. According to data from OpenAlex, Marinus van Oers has authored 17 papers receiving a total of 325 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Genetics, 7 papers in Hematology and 6 papers in Molecular Biology. Recurrent topics in Marinus van Oers's work include Chronic Lymphocytic Leukemia Research (9 papers), Multiple Myeloma Research and Treatments (6 papers) and Lymphoma Diagnosis and Treatment (6 papers). Marinus van Oers is often cited by papers focused on Chronic Lymphocytic Leukemia Research (9 papers), Multiple Myeloma Research and Treatments (6 papers) and Lymphoma Diagnosis and Treatment (6 papers). Marinus van Oers collaborates with scholars based in Netherlands, Denmark and United States. Marinus van Oers's co-authors include Arnon P. Kater, Thorsten Zenz, Florence Cymbalista, Stephan Stilgenbauer, John G. Gribben, David González, Hartmut Döhner, Peter Hillmen, Šárka Pospı́šilová and Barbara Eichhorst and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Haematology.

In The Last Decade

Marinus van Oers

17 papers receiving 320 citations

Peers

Marinus van Oers
Stefan Norin Sweden
Steve Pavletic United States
Nikola Tom Czechia
Dominique Penther France
Alexandra Oltová Czechia
G. García-Manero United States
Mutiah Apatira United States
Panagiotis Baliakas Sweden
T Kinoshita Japan
Tamia Nguyen Australia
Stefan Norin Sweden
Marinus van Oers
Citations per year, relative to Marinus van Oers Marinus van Oers (= 1×) peers Stefan Norin

Countries citing papers authored by Marinus van Oers

Since Specialization
Citations

This map shows the geographic impact of Marinus van Oers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marinus van Oers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marinus van Oers more than expected).

Fields of papers citing papers by Marinus van Oers

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marinus van Oers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marinus van Oers. The network helps show where Marinus van Oers may publish in the future.

Co-authorship network of co-authors of Marinus van Oers

This figure shows the co-authorship network connecting the top 25 collaborators of Marinus van Oers. A scholar is included among the top collaborators of Marinus van Oers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marinus van Oers. Marinus van Oers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Oers, Marinus van, Lukáš Smolej, Mario Petrini, et al.. (2019). Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study. Blood Cancer Journal. 9(12). 98–98. 10 indexed citations
2.
Preuss, Klaus‐Dieter, Carla E. M. Hollak, Natalie Fadle, et al.. (2018). Saposin C is a frequent target of paraproteins in Gaucher disease‐associated MGUS/multiple myeloma. British Journal of Haematology. 184(3). 384–391. 9 indexed citations
3.
Oers, Marinus van, Lukáš Smolej, Mario Petrini, et al.. (2018). Role of ofatumumab (OFA) maintenance treatment in relapsed chronic lymphocytic leukemia (CLL): Final analysis of PROLONG study.. Journal of Clinical Oncology. 36(15_suppl). 7517–7517. 1 indexed citations
4.
Kater, Arnon P., Jasmin Bahlo, Anna‐Maria Fink, et al.. (2018). The GAIA (CLL13) trial: An international intergroup phase III study for frontline therapy in chronic lymphocytic leukemia (CLL).. Journal of Clinical Oncology. 36(15_suppl). TPS7582–TPS7582. 8 indexed citations
5.
Eldering, Eric, Doreen te Raa, Veronika Navrkalová, et al.. (2014). SF3B1 mutations in CLL are associated with a defective DNAdamage response. 1 indexed citations
6.
Jethwa, Alexander, Jennifer Hüllein, Leopold Sellner, et al.. (2013). Targeted resequencing for analysis of clonal composition of recurrent gene mutations in chronic lymphocytic leukaemia. British Journal of Haematology. 163(4). 496–500. 31 indexed citations
7.
Pospı́šilová, Šárka, David González, Jitka Malčíková, et al.. (2012). ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. Leukemia. 26(7). 1458–1461. 133 indexed citations
8.
Vojdeman, Fie Juhl, Jesper Jurlander, Mars van’t Veer, et al.. (2012). Plasma alemtuzumab levels in patients with chronic lymphocytic leukemia treated with alemtuzumab combined with chemotherapy reflect the efficacy of the treatment: a hypothesis. Leukemia & lymphoma. 54(4). 790–793. 2 indexed citations
9.
Zeerleder, Sacha & Marinus van Oers. (2012). Aleukemic variant of mast cell leukemia. Blood. 119(9). 1961–1961. 1 indexed citations
10.
Lokhorst, Henk M., Bronno van der Holt, Jan J. Cornelissen, et al.. (2012). Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study. Blood. 119(26). 6219–6225. 72 indexed citations
11.
Lokhorst, H M, Pieter Sonneveld, Bronno van der Holt, et al.. (2010). FINAL DONOR VERSUS NO DONOR COMPARISON OF NEWLY DIAGNOSED MYELOMA PATIENTES INCLUDED IN THE HOVON 50/54 STUDY. Pure Amsterdam UMC. 95. 451–452. 2 indexed citations
12.
Lokhorst, H M, Pieter Sonneveld, Bronno van der Holt, et al.. (2009). A016 Donor Versus No-Donor Analysis of Newly Diagnosed Myeloma Patients included in the HOVON-50/54 Study. Clinical Lymphoma & Myeloma. 9. S5–S6. 4 indexed citations
13.
14.
Lokhorst, Henk M., Pieter Sonneveld, Bronno van der Holt, et al.. (2008). Donor Versus No Donor Analysis of Newly Diagnosed Myeloma Patients Included in the HOVON 50/54 Study. Blood. 112(11). 461–461. 11 indexed citations
15.
Sonneveld, Pieter, Bronno van der Holt, Christine M. Segeren, et al.. (2004). Intensive Versus Double Intensive Therapy in Untreated Multiple Myeloma: Updated Analysis of the Randomized Phase III Study HOVON 24 MM.. Blood. 104(11). 948–948. 8 indexed citations
16.
Oers, Marinus van, Anton Hagenbeek, M. van Glabbeke, & Ivana Teodorović. (2002). Chimeric anti-CD20 monoclonal antibody (Mabthera) in remission induction and maintenance treatment of relapsed follicular non-Hodgkin's lymphoma: a phase III randomized clinical trial - Intergroup Collaborative Study. Annals of Hematology. 81(10). 553–557. 20 indexed citations
17.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Stefan Norin Breakdown of academic impact, for papers by Steve Pavletic Breakdown of academic impact, for papers by Nikola Tom Breakdown of academic impact, for papers by Dominique Penther Breakdown of academic impact, for papers by Alexandra Oltová Breakdown of academic impact, for papers by G. García-Manero Breakdown of academic impact, for papers by Mutiah Apatira Breakdown of academic impact, for papers by Panagiotis Baliakas Breakdown of academic impact, for papers by T Kinoshita Breakdown of academic impact, for papers by Tamia Nguyen
Rankless by CCL
2026